The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved teprotumumab (Tepezza), the first medicine licensed ...

The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Vikas Goyal, MBA, promoted to Partner to lead growth stage investments in late preclinical and clinical stage biotechnology companies. BOSTON, MASSACHUSETTS / ACCESS Newswire / May 12, 2025 / Longwood ...

River Vision and Horizon developed Tepezza (teprotumumab) a new standard of care in the treatment of Grave's Orbitopathy and the first therapy ever approved for the indication. Earlier in his ...

The best outperformer of all, Tepezza, is the first pharmacotherapeutic ever for Thyroid Eye Disease, a rare but debilitating condition. Trikafta (also known as Kaftrio) for Cystic Fibrosis ...

Others include Amgen's Tepezza (tezepelumab) for thyroid eye disease, Takeda's Fruzaqla (fruquintinib) for advanced colorectal cancer, Eisai's Rozebalamin (mecobalamin) for amyotrophic lateral ...